Project Grant R01CA289581
Award Date
12/10/24
Completion Date
11/30/29
Dollars Obligated
$569K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Tampa, FL 33612, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Mayo Clinic to conduct preclinical and clinical research on a novel long-acting interleukin-7 (NT-I7) therapy in combination with anti-PD-1 checkpoint blockade for the treatment of glioblastoma. The $639,004 award, granted on January 1, 2025, will support specimen collection and comprehensive immunoprofiling studies to evaluate the mechanism of action and therapeutic efficacy...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $485,494 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to investigate the mechanisms by which non-canonical antigens, derived from novel unannotated open reading frames (NUORFs), are presented to the immune system in lung cancer. The overarching goal is to understand how these non-canonical antigens are synthesized, processed, and presented on MHC-I...
This Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), aims to evaluate the combination of external beam radiotherapy, autologous dendritic cell injections, and dual PD-L1/TIGIT blockade immunotherapy to improve treatment outcomes for patients with unresectable intrahepatic cholangiocarcinoma (ICCA). The $610,890 award, effective September 1, 2024 through August 31, 2029, will support a Phase II clinical study to...
This $459,867 project grant, awarded by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) on September 1, 2024, aims to create applied informatics technologies for cancer surveillance research and survivorship care in patients treated with immune checkpoint inhibitors (ICIs). The key products/services are: Conducting a clinical trial to assess the feasibility and effectiveness of informatics-assisted detection of immune-related adverse events (IRAEs) from...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) is funding research to overcome tumor-intrinsic mechanisms of immune evasion and boost the systemic response to radiotherapy for advanced cancers. The $577,818 award to the Mayo Clinic, with a project period from Sep 20, 2024 to Aug 31, 2029, will investigate the role of the immune checkpoint molecule B7-H3 in impairing T-cell mediated cytotoxicity and suppressing systemic anti-tumor immunity. The...
This National Cancer Institute (NCI) Project Grant award under the Cancer Biology Research program (CFDA 93.396) provides $680,334.00 to the Icahn School of Medicine at Mount Sinai (ISMMS) to conduct research aimed at elucidating the specific molecular mechanisms and cellular players driving age-associated pro-tumoral myelopoiesis. The 5-year project, starting on March 1, 2025, will involve high-dimensional profiling of tumors from early-stage lung cancer patients, multi-omics phenotyping of...
The federal Project Grant award R01AI182098, valued at $858,186.00, was granted by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award aims to decipher the mechanisms leading to immune-related myocarditis, a potentially fatal adverse event associated with immune checkpoint inhibitor (ICI) cancer therapies, and identify better mitigation strategies. The key activities involve using advanced...
The Project Grant award R21CA293969, titled "Modulating Intratumoral Immune Composition to Enhance Immunotherapy," was provided by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395). The $457,683 award, effective July 2, 2024 through June 30, 2026, supports research conducted by the Beckman Research Institute of the City of Hope to develop novel "bio-beacon" therapies that recruit and activate immune cells within solid...
The Project Grant award titled "Dissecting the Mechanism for Transient ER Stress-Induced Anti-Tumor T Cell Response" is funded by the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) federal grant program. The $626,534 award will support research at the Medical University of South Carolina (MUSC) to investigate how inducing transient endoplasmic reticulum (ER) stress can improve the anti-tumor function of T cells. The key objectives are to: Determine...
The National Cancer Institute awarded a $549,962 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. This 5-year grant, effective April 1, 2025, supports a research project to determine how antibodies and cellular ligands regulate the immunosuppressive function of the lymphocyte-activation gene 3 (LAG3) protein. The project aims to provide fundamental insights into LAG3 immunobiology...